Sotera Health revenue rises in Q1 as Sterigenics, Nordion offset Nelson Labs softness

Sotera Health Co. (SHC) reported first-quarter revenue growth that topped Wall Street expectations, helped by stronger Sterigenics performance and favorable Cobalt-60 harvest timing at Nordion, though investors reacted negatively to the results. Management cited pricing gains, resilient customer demand and operational execution as growth drivers, while flagging weather-related disruptions and softer testing volumes at Nelson Labs. CEO Michael Petras said March delivered the company’s strongest volume month in three to four years. Shares recently traded at $15.26, little changed from $15.39 before the earnings report. Investors are focused on Sterigenics’ capacity ramp, onboarding of a major customer, regulatory clarity on ethylene oxide emissions, margin trends and the pace of Nelson Labs’ volume recovery.